Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Phase 2a Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Orally Administered Investigational Capsid Inhibitor Monotherapy in HIV-1 Infected Treatment-Naïve Adults

NCT06039579 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT06039579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06039579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Phase 2a Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Orally Administered Investigational Capsid Inhibitor Monotherapy in HIV-1 Infected Treatment-Naïve Adults
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2023
Completion date
June 24, 2024
Enrollment
44 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections